Cellular targets for HIV infection
AssigneeAlbert Einstein College of Medicine
InventorsEliseo Eugenin, Joan W. Berman
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided for treating HIV infection and for inhibiting HIV infection, and for identifying purinergic receptor antagonists or Panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an HIV infection, or suspected of having been exposed to HIV, comprising administering to the mammalian subject an amount of (i) an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) HIV fusion with a target cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or more of (a), (b) and (c).
Claims4
A method of treating a mammalian subject having an HIV infection, or suspected of having been exposed to HIV, comprising administering to the mammalian subject an amount of a selective P2Y1 receptor inhibitor, wherein the inhibitor is MRS 2179 (2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate tetrasodium salt), MRS 2279 ((1R*,2S*)-4-[2-Chloro-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester diammonium salt), or MRS 2500 tetraammonium salt ((1R*,2S*)-4-[2-Iodo-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester tetraammonium salt).
Dependencies are inferred from the claim text.